Lineage Cell Therapeutics, Inc. (LCTX)
1.09
+0.01
(+0.93%)
USD |
NYAM |
Sep 08, 16:00
1.10
+0.01
(+0.92%)
Pre-Market: 08:04
Lineage Cell Therapeutics Shareholders Equity (Quarterly) : 60.92M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 60.92M |
| March 31, 2026 | 53.88M |
| December 31, 2025 | 44.55M |
| September 30, 2025 | 22.04M |
| June 30, 2025 | 48.38M |
| March 31, 2025 | 79.03M |
| December 31, 2024 | 78.38M |
| September 30, 2024 | 66.19M |
| June 30, 2024 | 68.30M |
| March 31, 2024 | 72.40M |
| December 31, 2023 | 63.42M |
| September 30, 2023 | 68.12M |
| June 30, 2023 | 72.67M |
| March 31, 2023 | 70.45M |
| December 31, 2022 | 73.34M |
| September 30, 2022 | 78.95M |
| June 30, 2022 | 82.85M |
| March 31, 2022 | 86.55M |
| December 31, 2021 | 92.22M |
| September 30, 2021 | 120.71M |
| June 30, 2021 | 124.71M |
| March 31, 2021 | 117.67M |
| December 31, 2020 | 96.20M |
| September 30, 2020 | 91.27M |
| June 30, 2020 | 99.44M |
| Date | Value |
|---|---|
| March 31, 2020 | 106.50M |
| December 31, 2019 | 112.96M |
| September 30, 2019 | 117.16M |
| June 30, 2019 | 133.39M |
| March 31, 2019 | 162.84M |
| December 31, 2018 | 93.84M |
| September 30, 2018 | 171.13M |
| June 30, 2018 | 100.98M |
| March 31, 2018 | 99.97M |
| December 31, 2017 | 162.64M |
| September 30, 2017 | 198.29M |
| June 30, 2017 | 176.12M |
| March 31, 2017 | 187.37M |
| December 31, 2016 | 117.93M |
| September 30, 2016 | 119.39M |
| June 30, 2016 | 85.74M |
| March 31, 2016 | 10.85M |
| December 31, 2015 | 26.89M |
| September 30, 2015 | 13.04M |
| June 30, 2015 | 16.98M |
| March 31, 2015 | 26.25M |
| December 31, 2014 | 36.46M |
| September 30, 2014 | 10.98M |
| June 30, 2014 | 17.91M |
| March 31, 2014 | 19.24M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
| Imunon, Inc. | 4.189M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 106.22M |
| Total Liabilities (Quarterly) | 46.42M |
| Debt to Equity Ratio | 0.0377 |
| Current Ratio | 6.608 |
| Net Debt Paydown Yield | 0.00% |